Bobenheim-Roxheim, Germany

Martin Behringer

This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Hoffmann-La Roche Inc.. Active years: 2017.

USPTO Granted Patents = 1 

 

 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2017

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Martin Behringer: Innovator in Chemical Recovery Processes

Introduction

Martin Behringer is a notable inventor based in Bobenheim-Roxheim, Germany. He has made significant contributions to the field of chemical recovery processes, particularly in the synthesis of acetylfuranoside. His innovative approach has implications for large-scale industrial applications.

Latest Patents

Behringer holds a patent for a process aimed at the recovery of beta-acetylfuranoside. This improved method allows for the extraction of residual, unseparated β-acetylfuranoside from reaction mixtures that remain after the initial synthesis. This process is particularly beneficial in the production of capecitabine, a drug used in cancer treatment.

Career Highlights

Throughout his career, Martin Behringer has worked with prominent companies in the pharmaceutical industry, including Hoffmann-La Roche Inc. and F. Hoffmann-La Roche AG. His experience in these organizations has contributed to his expertise in chemical processes and patent development.

Collaborations

Behringer has collaborated with notable professionals in his field, including Bernd Junghans and Bernhard Knipp. These partnerships have likely enhanced his research and development efforts.

Conclusion

Martin Behringer's contributions to the field of chemical recovery processes demonstrate his innovative spirit and commitment to advancing industrial applications. His work continues to impact the pharmaceutical industry positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…